Fact Source: Financial Supervisory Service DART / 2026-06-22
Disclosure Type: Manufacturing Agreement (Amendment)
💡 3-Second Summary
Samsung Biologics has amended its 2018 medicine contract manufacturing agreement upon the client’s request, shifting the total contract value from KRW 144.6B to KRW 215.9B and extending the contract period until the end of 2037.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Reason for Amendment: Modification of contract value and contract period as requested by the client.
- Contract Details (Contract Manufacturing Agreement):
- Contract Value: (Pre-amendment) KRW 144,610,010,460 ➔ (Post-amendment) KRW 215,942,414,460 (Increased by KRW 71,332,404,000)
- Ratio to Sales: (Pre-amendment) 31.12% ➔ (Post-amendment) 46.48% (Compared to the FY2017 consolidated sales of KRW 464,629,334,143)
- Value in USD: Increased by USD 62,920,000 from the previous USD 127,555,800, bringing the new fixed total to USD 190,475,800 (Applying the initial FX rate of 1,133.70 KRW/USD as of August 14, 2018).
- Contract Term & Confidentiality Period: (Pre-amendment) 2018-08-14 ~ 2028-12-31 ➔ (Post-amendment) 2018-08-14 ~ 2037-12-31
- Counterparty: A pharmaceutical company located in Asia (Identity undisclosed until December 31, 2037, due to business confidentiality).
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This filing details updates to the scale and duration of an existing corporate agreement. The contract manufacturing organization (CMO) agreement, signed initially in 2018, saw its value increase by approximately KRW 71.3B (USD 62.92M) and its expiration date deferred by nine years from 2028 to 2037, following a request from the client. The disclosure does not provide the specific internal drivers behind these performance adjustments.
Given the nature of long-term agreements, these adjustments may exert a potential impact on the company’s future backlog scheduling. However, market participants should note that the contract value and definitive timelines remain subject to change pending further mutual agreements. Furthermore, since the counterparty’s identity remains masked until 2037 due to confidentiality clauses, investors could focus on tracking subsequent regulatory filings and implementation updates.
📝 Editor’s Comment (by K-STOCK Editor)
A long-term contract signed in 2018 has been restructured through an increase in value and an extension of its duration upon the client’s request. The ratio against baseline sales adjusted upward from 31.12% to 46.48%, and the confidentiality period moved accordingly to 2037. It is important to emphasize that the filing states only the client’s request as the premise, without specifying any further operational motives, such as capacity reservation or additional funding details. Market participants may approach this with the understanding that long-term terms could potentially be re-adjusted later based on bilateral agreements.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
